Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Base de datos
Tipo del documento
Asunto de la revista
País de afiliación
Intervalo de año de publicación
2.
Exp Hematol ; 29(3): 330-8, 2001 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-11274761

RESUMEN

OBJECTIVE: The aim of the present study was to investigate the capacity of normal immune blood cells from non-Hodgkin's lymphoma patients to produce tumor necrosis factor (TNF) after lipopolysaccharide (LPS) stimulation and the influence of the TNF (-308) polymorphism in this production. MATERIALS AND METHODS: A whole peripheral blood cell assay was utilized following LPS stimulation. At selected incubation times, supernatants were harvested for protein dosage, while mRNA was extracted and reverse-transcribed. The amount of TNF mRNA was quantified using real-time quantitative polymerase chain reaction (PCR) and genomic DNA was typed for TNF (-308) polymorphism. RESULTS: Upon LPS stimulation, TNF-secreted protein was slightly but not significantly increased in lymphoma patients when compared to controls. In contrast, the relative TNF mRNA amounts were significantly higher in lymphoma patients at 30 minutes (median 27.75 vs. 16.00; Mann-Whitney U-test p < 0.05), at 4 hours (52.00 vs. 31.00; p < 0.05), and at 24 hours (19.50 vs. 9.00; p < 0.05). In addition, patients carrying the variant TNF2 allele had higher relative TNF mRNA levels than TNF1 homozygotes (p = 0.02). CONCLUSION: The LPS-induced TNF mRNA levels are higher in peripheral blood cells (PBC) from lymphoma patients than from controls, while TNF protein secretion is not strikingly different. Altered regulation of TNF mRNA translation or TNF protein secretion may contribute to these observations. Taken together, an increased susceptibility for TNF gene transcription after LPS stimulation was observed in PBC (mainly in monocytes) from lymphoma patients, and especially those carrying the TNF2 allele.


Asunto(s)
Regulación Neoplásica de la Expresión Génica/efectos de los fármacos , Leucocitos Mononucleares/química , Lipopolisacáridos/farmacología , Linfoma no Hodgkin/sangre , Proteínas de Neoplasias/genética , ARN Mensajero/sangre , ARN Neoplásico/sangre , Factor de Necrosis Tumoral alfa/genética , Adulto , Anciano , Alelos , ADN Complementario/genética , Dactinomicina/farmacología , Genotipo , Humanos , Leucocitos Mononucleares/metabolismo , Activación de Linfocitos/efectos de los fármacos , Linfoma no Hodgkin/genética , Persona de Mediana Edad , Proteínas de Neoplasias/biosíntesis , Proteínas de Neoplasias/metabolismo , Inhibidores de la Síntesis del Ácido Nucleico/farmacología , Reacción en Cadena de la Polimerasa , Factor de Necrosis Tumoral alfa/biosíntesis , Factor de Necrosis Tumoral alfa/metabolismo
3.
Cytokine ; 12(6): 762-4, 2000 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-10843760

RESUMEN

The pathogenesis of septic shock is mainly due to unregulated tumour necrosis factor-alpha (TNF-alpha) production. Procalcitonin (PCT) and calcitonin gene-related peptide (CGRP) are alternative transcription products of the calcitonin gene. Since high PCT levels have been described in human sepsis, and since CGRP inhibits TNF synthesis in rats, we examined the role of these peptides in the regulation of the inflammatory response during septic shock. LPS-induced TNF production was assessed using a human whole blood model. In this model, PCT (10(-7) M) and CGRP (10(-6) M) significantly inhibit TNF production by 27 and 24 % respectively. The effect of CGRP was reversed by CGRP 8-37 (10 microM), an antagonist of CGRP receptor. No effect on interleukin (IL)-1, IL-6 and IL-8 was found. This is the first description of an anti-inflammatory role for PCT and CGRP in humans.


Asunto(s)
Células Sanguíneas/fisiología , Péptido Relacionado con Gen de Calcitonina/farmacología , Calcitonina/farmacología , Lipopolisacáridos/toxicidad , Precursores de Proteínas/farmacología , Factor de Necrosis Tumoral alfa/biosíntesis , Animales , Células Sanguíneas/efectos de los fármacos , Células Sanguíneas/inmunología , Humanos , Interleucina-1/sangre , Interleucina-6/sangre , Interleucina-8/sangre , Fragmentos de Péptidos/farmacología , Ratas
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA